Pancreatic Cancer Research

ResearcherHokkaido UniversityActive in the last 2 years

Norio Katoh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3959-2114; OpenAlex author ID A5011553863, A5017571214. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 9

  1. Evaluation of the efficacy of plan adaptation in stereotactic body proton therapy for pancreatic cancer. Co-author DOI 10.1002/acm2.70644↗
  2. Japanese Nationwide Prospective Data of Proton Therapy for Liver Metastasis From Pancreatic Cancer. Last author DOI 10.1016/j.ijpt.2025.101291↗
  3. Fiducial Marker Placement for Gated Radiotherapy Using Real-Time Tumor-Tracking in Pancreatic Cancer: A Comparative Analysis of Transarterial and Percutaneous … Co-author DOI 10.1016/j.jvir.2025.08.018↗
  4. Normal tissue complication probability model for severe radiation-induced lymphopenia in patients with pancreatic cancer treated with concurrent chemoradiother… First author DOI 10.1016/j.phro.2024.100690↗
  5. Investigation of interfractional range variation owing to anatomical changes with beam directions based on water equivalent thickness in proton therapy for pan… Co-author DOI 10.1093/jrr/rrae069↗
  6. Evaluation of short-term gastrointestinal motion and its impact on dosimetric parameters in stereotactic body radiation therapy for pancreatic cancer. Co-author DOI 10.1016/j.ctro.2023.100576↗
  7. Predicting the daily gastrointestinal doses of stereotactic body radiation therapy for pancreatic cancer based on the shortest distance between the tumor and t… Co-author DOI 10.1259/bjro.20230043↗
  8. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderl… Co-author DOI 10.1016/j.ijrobp.2019.07.004↗
  9. R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy. Co-author DOI 10.21873/invivo.11362↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hidefumi Aoyama · 6 shared papers, 2023–2026 · strength 1.22
  2. Yusuke Uchinami · 5 shared papers, 2023–2026 · strength 0.99
  3. Seishin Takao · 2 shared papers, 2024–2026 · strength 0.50
  4. Fuki Koizumi · 3 shared papers, 2023–2025 · strength 0.49
  5. Yuto Matsuo · 1 shared paper, 2026 · strength 0.30
  6. Hisashi Yamaguchi · 1 shared paper, 2026 · strength 0.28
  7. Haruko Numajiri · 1 shared paper, 2026 · strength 0.28
  8. Nobuyoshi Fukumitsu · 1 shared paper, 2026 · strength 0.28
  9. Toru Nakamura · 2 shared papers, 2019–2025 · strength 0.27
  10. Kohsuke Kudo · 1 shared paper, 2025 · strength 0.23
  11. Daisuke Kato · 1 shared paper, 2025 · strength 0.23
  12. Yuhei Kikkawa · 1 shared paper, 2024 · strength 0.20
  13. Yasuyuki Kawamoto · 1 shared paper, 2025 · strength 0.19
  14. Hirofumi Kamachi · 1 shared paper, 2018 · strength 0.08
  15. Akinobu Taketomi · 1 shared paper, 2018 · strength 0.08
  16. Tsuyoshi Hayashi · 1 shared paper, 2019 · strength 0.08
  17. Makoto Yoshida · 1 shared paper, 2019 · strength 0.08
  18. Yasutoshi Kimura · 1 shared paper, 2019 · strength 0.08
  19. Hajime Yamazaki · 1 shared paper, 2019 · strength 0.08
  20. Akio Katanuma · 1 shared paper, 2019 · strength 0.08
  21. Satoshi Hirano · 1 shared paper, 2019 · strength 0.08
  22. Masayo Motoya · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.